| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6a6f422b091ba12ea61d4adbf1b0e8e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-44 |
| filingDate |
2018-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3200c60b53effa6f0f5aae6907267ab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8754bbff99838418ceabedd9eddb5395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b493bec9677595d53977c1a95a6829f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f540ff0f86fe08ac330be6b4199b97d |
| publicationDate |
2019-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-109200276-A |
| titleOfInvention |
A kind of application of flavin containing monooxygenase 2 in preparation treatment heart disease drug |
| abstract |
The invention discloses a kind of application of flavin containing monooxygenase 2 in preparation treatment heart disease drug; the present invention passes through the slow virus carrier for having transfected FMO2 overexpression; cardiac muscle cell high can express FMO2; compare control group; FMO2 is overexpressed inhibited to cardiomyocyte cell death caused by hypoxic-ischemic, hence it is evident that the cardiac function after improving myocardial infarction, FMO2 of the present invention have the protective effect to heart; inhibit the death of cardiac muscle cell, improves the function of heart after heart infarction. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110468144-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022037070-A1 |
| priorityDate |
2018-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |